Equities Analysts Set Expectations for Alumis Q3 Earnings

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Alumis in a note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.90) for the quarter, up from their previous forecast of ($1.38). The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis’ Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($3.71) EPS, FY2028 earnings at ($2.39) EPS and FY2029 earnings at ($1.14) EPS.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The company had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.80 million.

A number of other equities research analysts have also weighed in on the company. Oppenheimer cut their price objective on Alumis from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a research report on Saturday. Morgan Stanley cut their price objective on Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday. Guggenheim upgraded Alumis to a “buy” rating and set a $18.00 price objective on the stock in a research report on Tuesday, June 10th. Finally, Wells Fargo & Company began coverage on Alumis in a research report on Friday, July 25th. They issued an “overweight” rating and a $17.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $20.17.

Alumis Trading Up 8.2%

Shares of ALMS stock opened at $4.75 on Monday. Alumis has a fifty-two week low of $2.76 and a fifty-two week high of $13.11. The business’s 50 day moving average price is $3.59 and its 200-day moving average price is $4.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ALMS. Kera Capital Partners Inc. purchased a new position in shares of Alumis in the 2nd quarter valued at approximately $32,000. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Alumis by 199.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock valued at $32,000 after purchasing an additional 7,165 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Alumis by 173.7% in the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after purchasing an additional 7,467 shares during the period. Western Wealth Management LLC purchased a new position in Alumis during the second quarter valued at $36,000. Finally, ProShare Advisors LLC purchased a new position in Alumis during the second quarter valued at $40,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.